This is not the most recent version of the article. View current version (2 DEC 2014)

Intervention Protocol

You have free access to this content

Long term proton pump inhibitor (PPI) use and incidence of gastric premalignant lesions

  1. Huan Song1,*,
  2. DongHao Lu1,
  3. JianWei Zhu2

Editorial Group: Cochrane Upper Gastrointestinal and Pancreatic Diseases Group

Published Online: 26 JUN 2013

DOI: 10.1002/14651858.CD010623


How to Cite

Song H, Lu D, Zhu J. Long term proton pump inhibitor (PPI) use and incidence of gastric premalignant lesions (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD010623. DOI: 10.1002/14651858.CD010623.

Author Information

  1. 1

    Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden

  2. 2

    Shandong Provincial Hospital, Department of Orthopaedics, Jinan, Shandong, China

*Huan Song, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, Stockholm, SE-17177, Sweden. huan.song@ki.se.

Publication History

  1. Publication Status: New
  2. Published Online: 26 JUN 2013

SEARCH

This is not the most recent version of the article. View current version (02 DEC 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

  1. To compare the incidence of gastric premalignant lesions (i.e. atrophic gastritis, intestinal metaplasia and dysplasia) in patients on long-term (≥ 6 months) PPIs with those on no such therapy.
  2. To compare the incidence of gastric premalignant lesions in patients who had long-term PPI therapy with those without such treatment, in association with:
    1. presence of H. pylori infection;
    2. duration, type and dosage of PPI used;
    3. type of the underlying disease that the PPI is prescribed for (e.g. GERD, peptic ulcer disease).

  1. presence of H. pylori infection;
  2. duration, type and dosage of PPI used;
  3. type of the underlying disease that the PPI is prescribed for (e.g. GERD, peptic ulcer disease).